Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
News releases from Roivant Sciences
Roivant Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference
January 08, 2021
Recent milestones include first two FDA approvals at Vants launched by Roivant, positive clinical data at Dermavant, Aruvant, and Immunovant, and multiple computationally-designed protein degraders...
From
PR Newswire
Roivant Unveils Targeted Protein Degradation Platform
December 06, 2020
- First therapeutic candidate on track to enter clinical studies in 2021
From
PR Newswire
Roivant Provides Updates for Pivotal BREATHE Clinical Trial Evaluating Gimsilumab in COVID-19 Patients for the Prevention and Treatment of Acute Respiratory Distress Syndrome
May 13, 2020
-- Independent Data Monitoring Committee unanimously recommends trial continuation after pre-specified safety assessment
From
PR Newswire
Roivant Doses First Patient in Pivotal BREATHE Clinical Trial Evaluating Gimsilumab in COVID-19 Patients for the Prevention and Treatment of Acute Respiratory Distress Syndrome
April 15, 2020
- BREATHE is an adaptive, randomized, double-blind, placebo-controlled trial expected to enroll up to 270 patients, with a planned interim analysis
From
PR Newswire
Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody to Prevent and Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19
March 18, 2020
- Gimsilumab is a monoclonal antibody that targets GM-CSF, a pro-inflammatory cytokine found to be up-regulated in COVID-19 patients
From
PR Newswire
Roivant Launches Lokavant to Provide Real-Time and Anticipatory Clinical Trial Monitoring
January 13, 2020
- Lokavant has entered into multi-year enterprise license agreement with Parexel
From
PR Newswire
Roivant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 08, 2020
Roivant Sciences today announced that Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant, will present an overview of recent developments and future directions for the business at the 38th...
From
PR Newswire
Roivant Provides Corporate Updates in Advance of Second Annual Pipeline Day
June 05, 2019
Roivant Sciences today announced a series of corporate updates across the Roivant family of companies in advance of its second annual Pipeline Day tomorrow afternoon in New York City.
From
PR Newswire
Roivant Statement on Positive Phase 3 Results from Myovant's LIBERTY 1 Study in Uterine Fibroids
May 14, 2019
- Second annual Roivant Pipeline Day on June 6th to feature additional clinical data from across Roivant family of companies
From
PR Newswire
Roivant and Sinovant Launch Cytovant Sciences in Partnership with Medigene to Develop Cellular Therapies in Asia
April 04, 2019
- Cytovant licenses East Asian rights for a research-stage T-cell receptor (TCR) against tumor antigen NY-ESO-1 as well as rights for Medigene's dendritic cell (DC) vaccine for the treatment of...
From
PR Newswire
Roivant Statement on Topline Results from EMPOWUR Phase 3 Study in Overactive Bladder
March 19, 2019
- Vibegron met both co-primary endpoints and all seven key secondary endpoints
From
PR Newswire
Roivant Announces Corporate Updates and Webcast of Presentation at 37th Annual J.P. Morgan Healthcare Conference
January 06, 2019
From
PR Newswire
Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019
- In addition to Roivant, four Vants will be presenting at JPM this year
Tickers
AXON
MYOV
UROV
From
PR Newswire
Roivant Sciences and Daiichi Sankyo Enter into Broad Pipeline Partnership
December 18, 2018
Roivant Sciences today announced that it has entered into a collaboration with Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) to facilitate the out-licensing of investigational medicines....
Tickers
AXON
From
PR Newswire
Roivant Launches Aruvant Sciences and Roivant Foundation in Partnership with Cincinnati Children's Hospital Medical Center
November 26, 2018
- Aruvant's pipeline anchored by RVT-1801, an investigational gene therapy for sickle cell disease and ?-thalassemia
From
PR Newswire
Roivant Sciences and iNtRON Bio Sign Licensing Deal for Novel Anti-Superbugs Biologic SAL200
November 19, 2018
- Roivant plans to initiate Phase 2 clinical trial in 2019
From
PR Newswire
Roivant Sciences Announces $200 Million Investment Round
November 12, 2018
Roivant Sciences today announced a $200 million equity financing. New investors include NovaQuest Capital Management, RTW Investments, and other large institutional asset managers. These new investors...
From
PR Newswire
Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases
September 17, 2018
- Respivant to be led by Bill Gerhart, former CEO of Patara Pharma and Elevation Pharmaceuticals
Tickers
AXON
From
PR Newswire
Roivant Adds Investigational Therapeutic for the Treatment of Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis to Pipeline
September 04, 2018
- Statistically significant reduction in cough frequency observed among IPF patients after 14 days of treatment in completed Phase 2a trial
From
PR Newswire
Roivant Sciences Provides Corporate Update
August 28, 2018
- Dr. Frank Torti, former partner at NEA, appointed Vant Investment Chair
From
PR Newswire
Roivant Sciences Provides Corporate Updates in Advance of First Annual Pipeline Day
July 10, 2018
Roivant Sciences announced a series of corporate updates across the Roivant family of companies in advance of its first annual Pipeline Day this afternoon in New York City.
From
PR Newswire
Roivant Announces Creation of Roivant Pharma and Roivant Health and Launch of Altavant
June 26, 2018
- Roivant to increase focus on incubating and launching new Vants, including new companies focused on earlier-stage and potentially transformative scientific platforms
From
PR Newswire
Roivant to Host First Annual Pipeline Day
June 12, 2018
-- Event to highlight recent developments and future directions for Roivant
From
PR Newswire
Roivant Expands Senior Leadership with Key Hires
May 16, 2018
- Dr. Sam Azoulay, former SVP and Chief Medical Officer at Pfizer Essential Health, joins as Chief Medical Officer
From
PR Newswire
Roivant Sciences Enters into Development Partnership with AstraZeneca
October 19, 2017
Roivant Sciences today announced that it has entered into a development partnership with AstraZeneca for a deprioritized investigational drug in an undisclosed indication. The drug will be developed by...
From
PR Newswire
Roivant Sciences Statement on MINDSET Results
September 26, 2017
Today our subsidiary Axovant announced topline results from its Phase 3 MINDSET trial of intepirdine in mild-to-moderate Alzheimer's disease. Unfortunately, intepirdine did not achieve a statistically...
From
PR Newswire
Roivant Sciences Launches Datavant to Improve Clinical Trials with Artificial Intelligence
September 20, 2017
- Datavant aggregates and analyzes biomedical data to lower the time, cost, and risk of drug development
From
PR Newswire
Roivant Strengthens Executive Team with Key Hires and Promotions
September 13, 2017
- Former GC of Pfizer Allen Waxman joins Roivant
From
PR Newswire
Roivant Sciences Raises $1.1 Billion in Equity Investment Led by SoftBank Vision Fund
August 09, 2017
-- Investment to fuel creation of new subsidiaries within and beyond biopharmaceutical development, including new technology-enabled 'Vants'
From
PR Newswire
Roivant Sciences Launches Urovant to Develop Innovative Therapies in Urology
June 06, 2017
- Urovant has licensed vibegron, a Phase 3-ready selective ?3-adrenergic agonist for the treatment of overactive bladder, from Merck
From
PR Newswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.